Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Receptos Inc (NASDAQ:RCPT)

227.86
Delayed Data
As of Jul 31
 +0.38 / +0.17%
Today’s Change
40.00
Today|||52-Week Range
230.87
+85.99%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Other
MARKET CAP
$7.2B

Company Description

Receptos, Inc. is a biopharmaceutical company. It discovers, develops and commercializes innovative therapeutics for immune disorders. The company clinical pipeline includes RPC1063 and RPC4046. The RPC1063 is being developed as an oral therapy for the treatment of relapsing multiple sclerosis (RMS) and inflammatory bowel disease (IBD). The RPC4046 developed for the treatment of an allergic/immune-mediated disorder, eosinophilic esophagitis (EoE), which is an orphan disease. Receptos was founded by Marcus F. Boehm, Robert J. Peach, William H. Rastetter, Hugh Rosen and Raymond C. Stevens in 2009 and is headquartered in San Diego, CA.

Contact Information

Receptos, Inc.
3033 Science Park Road
San Diego California 92121
P:(858) 652-5700
Investor Relations:

Employees

Shareholders

Mutual fund holders49.50%
Other institutional42.79%
Individual stakeholders18.48%

Top Executives

Faheem HasnainPresident, Chief Executive Officer & Director
Graham K. CooperCFO, CAO, Head-Investor & Media Relations
Robert J. PeachChief Scientific Officer
Marcus F. BoehmChief Technology Officer
Sheila GujrathiChief Medical Officer